Developer docs
API playgroundTry for free, no card

Search company profiles

Probiogen

Full company profile

uuid0008wq8

Namestring
Probiogen
Legal namestring
ProBioGen AG
Websiteurl
probiogen.de
Company typeenum
Private
Founded yearint
1994
Descriptiontext

ProBioGen AG is a Berlin-based Contract Development and Manufacturing Organization (CDMO) serving biotech and pharmaceutical clients globally. Founded in 1994 as a spin-off from Charité hospital and operating as a wholly-owned subsidiary of Egypt's Minapharm Pharmaceuticals since 2010, ProBioGen specializes in cell line development, process development, and GMP manufacturing of therapeutic proteins, antibodies, viral vectors, and vaccines. The company employs approximately 300 staff across three manufacturing sites in Berlin-Weißensee, operating two 1000L single-use bioreactor GMP protein lines as of 2025 with viral manufacturing capacity to 200L.

ProBioGen's offering is anchored by a portfolio of proprietary technology platforms: CHO.RiGHT (CHO DG44-based expression system), DirectedLuck (transposase system for stable cell line development), GlymaxX (ADCC enhancement through glycoengineering, with the first GlymaxX-modified product FDA-approved in 2024), AGE1.CR.pIX and AGE1.CR.ReX (avian designer cell lines for viral vaccine production), Lenti.RiGHT (lentiviral packaging and producer cell line), and MVA-CR19 (poxvirus vector platform). The CMC Navigator framework structures CDMO engagements into four service models (Sprint, Scale, Customize, Rise) covering the pathway from first-in-human studies through scalable production. The company holds more than 15 patent families and reports over 400 stable cell lines developed to date.

ProBioGen operates two revenue streams: contract development and manufacturing services billed per project, and outbound licensing of proprietary technologies (non-exclusive licenses include GlymaxX to Boehringer Ingelheim and AGE1.CR.pIX to Transgene and GeoVax Labs). The company sells to enterprise biotech and pharma clients through a direct business development team led by VP Business Development Dr. Michiel Stork and CBO Dr. Gabriele Schneider, supported by participation in major industry events including the J.P. Morgan Healthcare Conference and BIO International Convention. Management cites over 70% repeat business and named customers spanning Marea Therapeutics, Zag Bio, Spica Therapeutics, Nouscom, Chiome Bioscience, Polpharma Biologics, Ridgeline Discovery, ModeX Therapeutics, and Boehringer Ingelheim.

Short descriptiontext

ProBioGen AG is a Berlin-based biopharmaceutical CDMO founded in 1994 as a Charité spin-off. It provides proprietary cell line development, process development, and GMP manufacturing services for therapeutic proteins, antibodies, viral vectors, and vaccines to biotech and pharma clients worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical CDMO services, cell line development, GMP manufacturing, viral vector production, therapeutic protein manufacturing
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services including cell line development, process development, GMP manufacturing, analytics, and bioassays for proteins, antibodies, viral vectors, and vaccines. Services offered as modular engagements from early development through commercial manufacturing.

probiogen.de
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies including AGE1.CR.pIX cell line, GlymaxX ADCC enhancement technology, CHO.RiGHT platform, and DirectedLuck transposase to other biopharma companies. Non-exclusive licenses granted to Boehringer Ingelheim (GlymaxX), GeoVax (AGE1.CR.pIX), and Transgene (AGE1.CR.pIX).

probiogen.de
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ProBioGen AG is a Contract Development and Manufacturing Organization (CDMO) that provides cell line engineering, process development, and GMP manufacturing of biopharmaceuticals (proteins, antibodies, viral vectors, and vaccines) for biotech and pharma clients. The company augments its CDMO services with proprietary technology platforms (CHO.RiGHT, GlymaxX, DirectedLuck, AGE1.CR.pIX, AGE1.CR.ReX, Lenti.RiGHT, MVA-CR19) that enhance product quality, expression yields, and ADCC potency, and it also licenses these technologies to third parties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • More than 70% of satisfied customers seen in repeat business
+5 more records
Product overview1 text field

ProBioGen is a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of proprietary technologies and services for biopharmaceutical development. The core portfolio consists of: (1) Proprietary Technology Platforms including CHO.RiGHT® (protein expression), DirectedLuck® (transposase system), GlymaxX® (ADCC enhancement/glycoengineering), MVA-CR19 (vector platform), Lenti.RiGHT® (lentiviral production), and AGE1.CR.pIX®/AGE1.CR.ReX® (avian designer cell lines for viral vaccines); (2) A comprehensive suite of CDMO services spanning cell line development, process development (USP/DSP), GMP manufacturing, analytics, and regulatory support for proteins, antibodies, viral vectors, and vaccines; and (3) The CMC Navigator™ framework providing four structured service models (Sprint, Scale, Customize, Rise) for flexible client engagement. The company operates three manufacturing lines in Berlin with capacity up to 2000L, serving clients from early development through commercial manufacturing.

Product and service1 record
1CHO.RiGHT® Producer Cell Line Platform
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Master Service Agreement for cell line development, process development, and GMP manufacturing for Zag Bio's ZAG-101 Fc-fusion autoimmune therapy targeting Type 1 diabetes. Clinical development targeted for late 2026. Zag Bio was founded in October 2024 and has secured $80 million including Series A financing.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Collaboration where ProBioGen performs GlymaxX-enhanced cell line development for Spica's clinical candidate ST101, an anti-CD163 antibody targeting tumor-associated macrophages. The partnership integrates ProBioGen's GlymaxX technology to enhance antibody ADCC activity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Memorandum of Understanding with IAVI and Minapharm to develop and manufacture vaccines and biologics in Africa, focusing on Mpox and HIV. Initiative aims to strengthen local manufacturing and improve access to vaccines through technology transfers and collaborations with regional health organizations.

4Berlin Center for Gene and Cell Therapies (BC GCT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

ProBioGen to lead GMP manufacturing operations at the Berlin Center for Gene and Cell Therapies, a project led by Bayer AG, Charité, and Berlin Institute of Health. Represents major strategic expansion into cell therapy manufacturing.

bayer.com
5Transgene
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-01
Description

License agreement for ProBioGen's AGE1.CR.pIX suspension cell line to support Transgene's individualized cancer vaccine program and myvac platform. Combines ProBioGen's production technology with Transgene's manufacturing capabilities.

probiogen.de
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

ProBioGen provided expertise for accelerated COVID-19 antibody development, including innovative cell engineering solutions.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-09-01
Description

Multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line to bolster MVA-based vaccine development. GeoVax is a biotechnology company developing vaccines and immunotherapies.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-05-01
Description

ProBioGen's AGE1.CR.pIX production platform successfully used to manufacture viral vector product for Nouscom's clinical Phase II trial.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

CDMO partnership for development of IgG1 antibody for autoimmune and cancer indications. Partnership demonstrated importance of collaboration and open communication in CDMO projects.

10Boehringer Ingelheim
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Non-exclusive license for ProBioGen's proprietary GlymaxX ADCC enhancement technology to produce antibodies with enhanced ADCC potency.

probiogen.de
Strategic tierMajorTypeTechnology or Integration
Description

ProBioGen engineered the Freedom CHO-S Kit platform in close collaboration with Thermo Fisher Scientific. The kit enables cost-and-time-efficient stable cell line development for research and commercial purposes and is available via Thermo Fisher Scientific.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Agreement for ProBioGen to provide high-performance cell line development services using CHO.RiGHT platform and proprietary technologies.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeOthers
TypeDirect peer
Description

German-headquartered, mid-sized CDMO focused on mammalian cell culture, process development and GMP manufacturing for therapeutic proteins and antibodies. Most direct strategic comparable — similar size, German quality positioning, biologics-only focus, and family/strategic ownership structure.

TypeDirect peer
Description

European biopharmaceutical CDMO offering cell line development, process development and GMP manufacturing for biologics, with new lentiviral vector capacity. Comparable service portfolio, similar size and German-speaking roots; new COO Dr. Simon Bulling joins ProBioGen from Celonic, signaling close competitive overlap.

TypeDirect peer
Description

Global CDMO with mammalian and microbial biologics manufacturing plus viral vector (lentivirus, AAV) capabilities. Directly competes with ProBioGen across both protein and viral vector CDMO services, but at significantly larger scale.

5Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Global large-molecule CDMO inside a major pharma group, offering mammalian cell culture, viral vector and microbial services. Broader portfolio than ProBioGen and existing GlymaxX licensee, so it competes and partners simultaneously with the company.

TypeDirect peer
Description

Specialist viral vector CDMO focused on lentiviral vectors for cell and gene therapy. Most relevant pure-play comparator for ProBioGen's Lenti.RiGHT and AAV services, though at a larger scale and listed.

7Cobra Biologics (Charles River Laboratories)
TypeBroad incumbent
Description

Part of Charles River's CDMO segment, providing viral vector and plasmid DNA manufacturing. Directly comparable for ProBioGen's gene therapy CDMO offering, backed by a much larger parent.

TypeBroad incumbent
Description

Large-scale biologics CDMO with cell line development, process development and GMP manufacturing including viral vectors. Competes head-to-head on mammalian biologics with much larger commercial-scale capacity.

TypeRegional player
Description

Egyptian biopharmaceutical company and ProBioGen's parent since 2010. Owns large-scale commercial manufacturing capacity in Egypt/MENA that ProBioGen leverages for late-stage and commercial supply — a sibling/parent relationship rather than direct competitor.

TypeBroad incumbent
Description

Global CDMO via Patheon plus a major life-science tools vendor with whom ProBioGen co-developed the Freedom CHO-S Kit. Competes across biologics services while also serving as a strategic distribution and supply partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Probiogen

Biopharmaceutical CDMO Servicesprobiogen.de

ProBioGen AG is a Berlin-based biopharmaceutical CDMO founded in 1994 as a Charité spin-off. It provides proprietary cell line development, process development, and GMP manufacturing services for therapeutic proteins, antibodies, viral vectors, and vaccines to biotech and pharma clients worldwide.

What Probiogen does

ProBioGen AG is a Berlin-based Contract Development and Manufacturing Organization (CDMO) serving biotech and pharmaceutical clients globally. Founded in 1994 as a spin-off from Charité hospital and operating as a wholly-owned subsidiary of Egypt's Minapharm Pharmaceuticals since 2010, ProBioGen specializes in cell line development, process development, and GMP manufacturing of therapeutic proteins, antibodies, viral vectors, and vaccines. The company employs approximately 300 staff across three manufacturing sites in Berlin-Weißensee, operating two 1000L single-use bioreactor GMP protein lines as of 2025 with viral manufacturing capacity to 200L.

ProBioGen's offering is anchored by a portfolio of proprietary technology platforms: CHO.RiGHT (CHO DG44-based expression system), DirectedLuck (transposase system for stable cell line development), GlymaxX (ADCC enhancement through glycoengineering, with the first GlymaxX-modified product FDA-approved in 2024), AGE1.CR.pIX and AGE1.CR.ReX (avian designer cell lines for viral vaccine production), Lenti.RiGHT (lentiviral packaging and producer cell line), and MVA-CR19 (poxvirus vector platform). The CMC Navigator framework structures CDMO engagements into four service models (Sprint, Scale, Customize, Rise) covering the pathway from first-in-human studies through scalable production. The company holds more than 15 patent families and reports over 400 stable cell lines developed to date.

ProBioGen operates two revenue streams: contract development and manufacturing services billed per project, and outbound licensing of proprietary technologies (non-exclusive licenses include GlymaxX to Boehringer Ingelheim and AGE1.CR.pIX to Transgene and GeoVax Labs). The company sells to enterprise biotech and pharma clients through a direct business development team led by VP Business Development Dr. Michiel Stork and CBO Dr. Gabriele Schneider, supported by participation in major industry events including the J.P. Morgan Healthcare Conference and BIO International Convention. Management cites over 70% repeat business and named customers spanning Marea Therapeutics, Zag Bio, Spica Therapeutics, Nouscom, Chiome Bioscience, Polpharma Biologics, Ridgeline Discovery, ModeX Therapeutics, and Boehringer Ingelheim.

Probiogen firmographics

Firmographics
Name
Probiogen
Legal name
ProBioGen AG
Website
https://probiogen.de
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
101–250 employees
Short description
ProBioGen AG is a Berlin-based biopharmaceutical CDMO founded in 1994 as a Charité spin-off. It provides proprietary cell line development, process development, and GMP manufacturing services for therapeutic proteins, antibodies, viral vectors, and vaccines to biotech and pharma clients worldwide.
Ownership category
akta.pro rank

Probiogen industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Biopharmaceutical CDMO services
  • Cell line development
  • GMP manufacturing
  • Viral vector production
  • Therapeutic protein manufacturing

Where Probiogen is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

Probiogen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO Services: Contract development and manufacturing services including cell line development, process development, GMP manufacturing, analytics, and bioassays for proteins, antibodies, viral vectors, and vaccines. Services offered as modular engagements from early development through commercial manufacturing.
  2. Technology Licensing: Licensing of proprietary technologies including AGE1.CR.pIX cell line, GlymaxX ADCC enhancement technology, CHO.RiGHT platform, and DirectedLuck transposase to other biopharma companies. Non-exclusive licenses granted to Boehringer Ingelheim (GlymaxX), GeoVax (AGE1.CR.pIX), and Transgene (AGE1.CR.pIX).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Probiogen product offering

Product offering

Core offering

ProBioGen AG is a Contract Development and Manufacturing Organization (CDMO) that provides cell line engineering, process development, and GMP manufacturing of biopharmaceuticals (proteins, antibodies, viral vectors, and vaccines) for biotech and pharma clients. The company augments its CDMO services with proprietary technology platforms (CHO.RiGHT, GlymaxX, DirectedLuck, AGE1.CR.pIX, AGE1.CR.ReX, Lenti.RiGHT, MVA-CR19) that enhance product quality, expression yields, and ADCC potency, and it also licenses these technologies to third parties.

Product overview

ProBioGen is a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of proprietary technologies and services for biopharmaceutical development. The core portfolio consists of: (1) Proprietary Technology Platforms including CHO.RiGHT® (protein expression), DirectedLuck® (transposase system), GlymaxX® (ADCC enhancement/glycoengineering), MVA-CR19 (vector platform), Lenti.RiGHT® (lentiviral production), and AGE1.CR.pIX®/AGE1.CR.ReX® (avian designer cell lines for viral vaccines); (2) A comprehensive suite of CDMO services spanning cell line development, process development (USP/DSP), GMP manufacturing, analytics, and regulatory support for proteins, antibodies, viral vectors, and vaccines; and (3) The CMC Navigator™ framework providing four structured service models (Sprint, Scale, Customize, Rise) for flexible client engagement. The company operates three manufacturing lines in Berlin with capacity up to 2000L, serving clients from early development through commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • CHO.RiGHT® Producer Cell Line Platform

Quantifiable outcome

  • More than 70% of satisfied customers seen in repeat business
  • +5 more outcomes

Companies that use Probiogen

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles4 records

Probiogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Probiogen partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

  • Zag BiocoreStrategic or Co-development Partner · 1 January 2026Master Service Agreement for cell line development, process development, and GMP manufacturing for Zag Bio's ZAG-101 Fc-fusion autoimmune therapy targeting Type 1 diabetes. Clinical development targeted for late 2026. Zag Bio was founded in October 2024 and has secured $80 million including Series A financing.
  • Spica TherapeuticsmajorStrategic or Co-development Partner · 1 December 2025Collaboration where ProBioGen performs GlymaxX-enhanced cell line development for Spica's clinical candidate ST101, an anti-CD163 antibody targeting tumor-associated macrophages. The partnership integrates ProBioGen's GlymaxX technology to enhance antibody ADCC activity.
  • IAVIcoreStrategic or Co-development Partner · 1 October 2025Memorandum of Understanding with IAVI and Minapharm to develop and manufacture vaccines and biologics in Africa, focusing on Mpox and HIV. Initiative aims to strengthen local manufacturing and improve access to vaccines through technology transfers and collaborations with regional health organizations.
  • Berlin Center for Gene and Cell Therapies (BC GCT)coreStrategic or Co-development Partner · 1 January 2025ProBioGen to lead GMP manufacturing operations at the Berlin Center for Gene and Cell Therapies, a project led by Bayer AG, Charité, and Berlin Institute of Health. Represents major strategic expansion into cell therapy manufacturing.
  • TransgenemajorOEM/ Whitelabel/ Licensing Partner · 1 November 2024License agreement for ProBioGen's AGE1.CR.pIX suspension cell line to support Transgene's individualized cancer vaccine program and myvac platform. Combines ProBioGen's production technology with Transgene's manufacturing capabilities.
  • ModeX TherapeuticsminorStrategic or Co-development Partner · 1 May 2024ProBioGen provided expertise for accelerated COVID-19 antibody development, including innovative cell engineering solutions.
  • GeoVax LabsmajorOEM/ Whitelabel/ Licensing Partner · 1 September 2023Multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line to bolster MVA-based vaccine development. GeoVax is a biotechnology company developing vaccines and immunotherapies.
  • NouscommajorTechnology or Integration · 1 May 2023ProBioGen's AGE1.CR.pIX production platform successfully used to manufacture viral vector product for Nouscom's clinical Phase II trial.
  • Ridgeline Discovery (Versant Ventures)majorStrategic or Co-development Partner · 1 January 2023CDMO partnership for development of IgG1 antibody for autoimmune and cancer indications. Partnership demonstrated importance of collaboration and open communication in CDMO projects.
  • Boehringer IngelheimmajorOEM/ Whitelabel/ Licensing PartnerNon-exclusive license for ProBioGen's proprietary GlymaxX ADCC enhancement technology to produce antibodies with enhanced ADCC potency.
  • Thermo Fisher ScientificmajorTechnology or IntegrationProBioGen engineered the Freedom CHO-S Kit platform in close collaboration with Thermo Fisher Scientific. The kit enables cost-and-time-efficient stable cell line development for research and commercial purposes and is available via Thermo Fisher Scientific.
  • Polpharma BiologicsmajorStrategic or Co-development PartnerAgreement for ProBioGen to provide high-performance cell line development services using CHO.RiGHT platform and proprietary technologies.

Scale indicators8 records

Recent moves12 records

Expansion highlights7 records

Probiogen competitors and assessment

Company assessment

Others

Direct peers

  • Rentschler Biopharma: German-headquartered, mid-sized CDMO focused on mammalian cell culture, process development and GMP manufacturing for therapeutic proteins and antibodies. Most direct strategic comparable — similar size, German quality positioning, biologics-only focus, and family/strategic ownership structure.
  • Celonic: European biopharmaceutical CDMO offering cell line development, process development and GMP manufacturing for biologics, with new lentiviral vector capacity. Comparable service portfolio, similar size and German-speaking roots; new COO Dr. Simon Bulling joins ProBioGen from Celonic, signaling close competitive overlap.
  • AGC Biologics: Global CDMO with mammalian and microbial biologics manufacturing plus viral vector (lentivirus, AAV) capabilities. Directly competes with ProBioGen across both protein and viral vector CDMO services, but at significantly larger scale.
  • Oxford Biomedica: Specialist viral vector CDMO focused on lentiviral vectors for cell and gene therapy. Most relevant pure-play comparator for ProBioGen's Lenti.RiGHT and AAV services, though at a larger scale and listed.

Broad incumbents

  • Boehringer Ingelheim BioXcellence: Global large-molecule CDMO inside a major pharma group, offering mammalian cell culture, viral vector and microbial services. Broader portfolio than ProBioGen and existing GlymaxX licensee, so it competes and partners simultaneously with the company.
  • Cobra Biologics (Charles River Laboratories): Part of Charles River's CDMO segment, providing viral vector and plasmid DNA manufacturing. Directly comparable for ProBioGen's gene therapy CDMO offering, backed by a much larger parent.
  • Fujifilm Diosynth Biotechnologies: Large-scale biologics CDMO with cell line development, process development and GMP manufacturing including viral vectors. Competes head-to-head on mammalian biologics with much larger commercial-scale capacity.
  • Thermo Fisher Scientific (Patheon Biologics): Global CDMO via Patheon plus a major life-science tools vendor with whom ProBioGen co-developed the Freedom CHO-S Kit. Competes across biologics services while also serving as a strategic distribution and supply partner.

Regional players

  • Minapharm Pharmaceuticals: Egyptian biopharmaceutical company and ProBioGen's parent since 2010. Owns large-scale commercial manufacturing capacity in Egypt/MENA that ProBioGen leverages for late-stage and commercial supply — a sibling/parent relationship rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Probiogen social profiles

Digital presence

Probiogen compliance and trust

Trust signal

Compliance1 record

Probiogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Probiogen leadership team

Management profile

Number of profiles

Profiles9 records

Probiogen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Probiogen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Probiogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Probiogen

What does Probiogen do?

ProBioGen AG is a Contract Development and Manufacturing Organization (CDMO) that provides cell line engineering, process development, and GMP manufacturing of biopharmaceuticals (proteins, antibodies, viral vectors, and vaccines) for biotech and pharma clients. The company augments its CDMO services with proprietary technology platforms (CHO.RiGHT, GlymaxX, DirectedLuck, AGE1.CR.pIX, AGE1.CR.ReX, Lenti.RiGHT, MVA-CR19) that enhance product quality, expression yields, and ADCC potency, and it also licenses these technologies to third parties.

Is Probiogen a public or private company?

Probiogen is a private company. It is classified as corporate owned and is currently operating.

When was Probiogen founded?

Probiogen was founded in 1994. It employs 101 to 250 people.

Where is Probiogen based?

Probiogen is headquartered in Berlin, Germany, in the Europe region.

How does Probiogen make money?

Two revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing.

Who are Probiogen's main competitors?

Lonza Biologics is listed as an others. Direct peers are Rentschler Biopharma, Celonic, AGC Biologics and Oxford Biomedica. Broad incumbents are Boehringer Ingelheim BioXcellence, Cobra Biologics (Charles River Laboratories), Fujifilm Diosynth Biotechnologies and Thermo Fisher Scientific (Patheon Biologics). Minapharm Pharmaceuticals is listed as a regional player.

Does Probiogen have an API?

No public API is recorded for Probiogen.

What industry is Probiogen in?

Probiogen's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell LineProBioGen and Transgene broadened their collaboration to include an additional license for ProBioGen's AGE1.CR.pIX cell line, designed to boost Transgene's manufacturing capabilities. The cell line, derived from duck embryo cells, is optimized for viral vaccine production in chemically defined, animal-component-free medium. Transgene's clinical-stage programs include TG4050 and TG4070 vaccines.PharmafileCEPI backs African-led Bundibugyo Ebola vaccine developmentCEPI will fund up to $16.5 million for Minapharm's development of a vaccine against Bundibugyo ebolavirus, advancing it through preclinical work and a phase 1 trial in Africa. The vaccine, designed by ProBioGen, is the fifth candidate supported by CEPI for the current outbreak in DRC. If successful, later-stage trials will aim for emergency-use authorization.News-MedicalAfrican Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trialsMinapharm Group, an Egyptian biopharmaceutical company with a Berlin subsidiary, will receive up to US$16.5 million from CEPI to advance a Bundibugyo ebolavirus vaccine candidate into a Phase 1 clinical trial. The vaccine, built on ProBioGen's MVA-CR19 platform, is the fifth CEPI-supported Bundibugyo candidate and the only one targeting both B- and T-cell responses. CEPI aims to bring at least two candidates to Emergency Use Authorization.Local BreakingEgyptian pharmaceutical firm developing Ebola vaccineEgyptian pharmaceutical firm Minapharm announced it will receive up to $16.5 million from CEPI to develop a vaccine against the Bundibugyo strain of Ebola in the Democratic Republic of Congo, with the Berlin-based ProBioGen subsidiary designing the candidate. The funding will advance the MVA-platform vaccine through laboratory stages to a Phase 1 trial in Africa. CEPI is funding four other Bundibugyo candidates, and hopes at least two will reach WHO approval.FolhaGrupo egípcio desenvolve vacina contra o ebolaEgyptian pharmaceutical company Minapharm announced it will receive up to US$16.5 million from CEPI to advance a vaccine candidate against the Bundibugyo ebola strain, which is spreading in the Democratic Republic of Congo. The Berlin-based subsidiary ProBioGen's MVA-based vaccine is the fifth CEPI-funded candidate, with no approved treatments. Over 5,600 cases and more than 2,700 deaths have been confirmed since May 15.ReutersCEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million fundingCEPI announced it will provide up to $16.5 million to Egypt-based Minapharm Group to advance an experimental Bundibugyo Ebola vaccine into human trials in Africa. The vaccine, developed by Minapharm's Berlin unit ProBioGen using its MVA-CR19 platform, will undergo safety and immune-response testing, with manufacturing initially in Germany and packaging in Cairo. CEPI aims to advance at least two Bundibugyo vaccines toward emergency authorization.AijournAfrican Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trialsMinapharm Group, an Egyptian biopharmaceutical company with a Berlin subsidiary, received up to US$16.5 million from CEPI to advance a Bundibugyo ebolavirus vaccine candidate into a Phase 1 clinical trial. The vaccine is built on ProBioGen's proprietary MVA-CR19 platform, and the trial is expected to take place in Africa. CEPI aims to bring at least two Bundibugyo vaccines to Emergency Use Authorisation and WHO prequalification.CepiAfrican Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trialsCEPI awarded up to $16.5 million to Minapharm to advance a Bundibugyo ebolavirus vaccine candidate into a Phase 1 clinical trial. The vaccine, based on ProBioGen's MVA-CR19 platform, is the fifth CEPI-supported candidate and aims to induce both B- and T-cell responses. CEPI expects to bring at least two candidates to Emergency Use Authorisation.PR NewswireAfrican Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trialsCEPI awarded up to $16.5 million to Minapharm to advance a Bundibugyo ebolavirus vaccine candidate into a Phase 1 clinical trial. The vaccine, based on ProBioGen's MVA-CR19 platform, is the fifth CEPI-backed candidate and the only one designed to induce both B- and T-cell responses. CEPI aims to bring at least two vaccines to emergency use authorization.European BiotechnologyBerlin-developed Ebola vaccine heads toward African trialCEPI is funding Minapharm's Berlin-based ProBioGen to advance a Bundibugyo Ebola vaccine candidate into clinical development, with up to $16.5 million. A Phase I trial is planned in Africa, as the current outbreak has infected nearly 5,000 people and killed over 2,300. The project aims to build African manufacturing capacity for future outbreaks.